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Abstract
Background: A common variant of the UMOD gene was linked with prevalent chronic kidney disease (CKD) in
large, genomics consortia. One community-based study found that urine concentrations of the uromodulin protein
forecast risk of incident CKD. This study within persons with known coronary artery disease (CAD) evaluated
whether uromodulin concentrations could distinguish CKD risk.
Methods: In the Heart and Soul Study, the UMOD snp (12917707) was genotyped in 879 individuals with baseline
creatinine clearance (CrCl) measured from a 24-hour urine collection. Uromodulin protein was measured from
stored urine specimens among a subset of 120 participants, balanced by genotype. Incident CKD cases (N = 102)
were defined by an initial CrCl > 70 ml/min and a 5-year follow-up CrCl <60 ml/min; controls (N = 94) were
matched on age, sex, and race.
Results: Among 527 self-described White participants with DNA, 373 (71%) were homozygous for the dominant
allele (G/G), 133 (25%) were heterozygous (G/T) and only 21 (4%) were homozygous for the minor allele (T/T). The
T/T genotype had an approximately 11 ml/min higher CrCl than the other 2 groups, but this difference did not
reach statistical significance (p = 0.20). The T/T genotype had significantly lower uromodulin levels than the
common G/G genotype, and the G/T genotype had intermediate levels. However, uromodulin concentrations were
similar between cases and controls (44 vs. 48 mg/dL, p = 0.88).
Conclusions: This study among a cohort of persons with established CAD found no association between urine
uromodulin and incident CKD, although UMOD genotype was associated with urine uromodulin concentrations.
Background
A common variant in the region of the UMOD gene
was recently discovered in association with chronic kid-
ney disease (CKD) in the Cohorts for Heart and Aging
Research in Genomic Epidemiology (CHARGE) Consor-
tium of 19,877 participants of European ancestry. [1]
This finding was further validated in the CKDGen colla-
boration of 67,093 participants, also of European ances-
try. [1,2] Each copy of the minor allele (frequency of
0.18) was associated with 20% lower odds of CKD across
these population-based studies. Prior studies have found
that rare mutations in the UMOD gene cause at least
two forms of autosomal dominant hereditary kidney
disease that progress into end-stage renal disease
(ESRD) (familial juvenile hyperuricemicnephropathy and
a form of medullary cystic kidney disease). The UMOD
gene codes the protein uromodulin, also known as
Tamm Horsfall Protein (THP), which is the most abun-
dant urinary protein in healthy individuals. In the famil-
ial disorders with mutations in the UMOD gene, a
mutant uromodulin protein is produced that is retained
in the endoplasmic reticulum, leading to decreased
expression on the apical plasma membrane and
decreased levels in the urine. [3,4]
To evaluate urine uromodulin concentrations as an
indicator of CKD risk, CHARGE investigators recently
measured uromodulin levels in the Framingham Heart
Study (FHS) and the Atherosclerosis Risk in Commu-
nities (ARIC) Study. [5] In both FHS and ARIC the pro-
tective genotype was associated with lower urine
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control design for incident CKD in FHS, baseline
concentrations of uromodulin were significantly and
independently higher among participants who subse-
quently developed CKD over 10 years of follow-up, as
defined by a creatinine-based estimated glomerular fil-
tration rate (eGFR) < 60 ml/min/1.73 m
2.W h e t h e ro r
not the findings from FHS, a community-based study,
extend across other settings is an important question to
understand the potential of uromodulin protein as a
biomarker for kidney disease onset and progression.
Patients with cardiovascular disease are a population
at high risk for developing CKD [6,7]. Atherosclerosis in
both large arteries and in the microvasculature appears
to contribute to declining kidney function [8,9]. In the
Heart and Soul Study, a well-characterized cohort of
persons with established coronary artery disease (CAD),
we evaluated whether baseline urine uromodulin con-
centrations would distinguish participants with and
without subsequent progression to CKD after 5 years of
follow-up. [10] In addition, we evaluated whether
UMOD genotype was associated with urine concentra-
tions of uromodulin in these participants.
Methods
Heart and Soul Description
The Heart and Soul Study is an observational study ori-
ginally designed to investigate the influence of psychoso-
cial factors on the progression of CAD. Methods have
been described previously. [10] Briefly, participants were
recruited from outpatient clinics in the San Francisco
Bay area if they met one of the following inclusion cri-
teria: history of myocardial infarction, angiographic evi-
dence of >50% stenosis in ≥1 coronary vessels, evidence
of exercise-induced ischemia by treadmill or nuclear
testing, history of coronary revascularization, or docu-
mented diagnosis of CAD by an internist or cardiologist.
Participants were excluded if they were not able to walk
1 block, had experienced myocardial infarction within
t h ep a s t6m o n t h s ,o rw e r el i k e l yt om o v eo u to ft h e
area within 3 years. The study protocol was approved by
the Institutional Review Boards of participating institu-
tions, and all participants provided written informed
consent. Between September 2000 and December 2002,
1024 participants enrolled and underwent a day-long
baseline study appointment that included a medical his-
tory, physical examination, and comprehensive health
status questionnaire. Of these, 982 participants provided
DNA samples, and 879 of these provided 24-hour timed
urine collections. After 5 years of follow-up, all surviving
participants were invited to return for a repeat examina-
tion. Of the original 1024 enrollees, 195 had died before
the 5-year examination. Between September 2005 and
December 2007, 667 (80%) of the surviving 829 partici-
pants completed the 5-year follow-up examination.
Design
The initial step of this study was to genotype the rele-
vant UMOD sNP (rs12917707) identified from the
CHARGE analysis across all Heart and Soul participants
with available stored DNA and 24-hour urine samples
(N = 879). In study 1, we evaluated the cross-sectional
association of genotype with baseline creatinine clear-
ance among all persons with available urine samples. In
study 2, we evaluated whether the genotype at sNP
(rs12917707) was associated with urine concentrations
of uromodulin, as previously described in FHS and
ARIC. In this analysis, we measured uromodulin con-
centrations among all participants who were homozy-
gous for the minor allele (T/T, n = 24) and among
48 participants each who were heterozygous (G/T) or
homozygous for the dominant allele (G/G). In study 3,
we used a nested case-control design to determine
whether urine uromodulin levels were associated with
incidence of CKD. We identified cases defined by an
initial measured creatinine clearance (CrCl) of > 70 ml/
min and CrCl < 60 ml/min after 5 years of follow-up.
For each case participant, a control was selected who
was matched on age, sex, and race. We chose not to
match on urine albumin excretion, so that we could
compare it with urine uromodulin as a predictor of inci-
dent CKD. Urine uromodulin levels were then measured
from baseline stored specimens with the technician
blinded to case and control status. Stored urine
specimens were available from 102 of the cases and
94 controls.
Genotyping Methods
Of the 1024 participants, 982 individuals provided DNA
for analysis. The SNP marker for rs12917707 was geno-
typed using TaqMan
® SNP Genotyping Assays (Applied
Biosystems, Foster City, CA, http://www.appliedbiosys-
tems.com) functionally tested by Applied Biosystems and
available on demand. TaqMan
® PCR reactions were done
with Universal Master Mix Amperase
® UNG, 0.083 uL
Taqman 40× probe mix and 1.417 uL of water, 1 ul of
DNA normalized to 10 ng/ul, for a 5 uL total volume.
The PCR conditions for the TaqMan
® SNP Genotype
Assays were: one enzyme activation step at 95.0°C for ten
minutes, and 50 alternating cycles of denaturation at
95.0°C for 15 seconds and reannealing and extension at
60.0°C for one minute. All PCR reactions and allelic dis-
crimination reactions were performed on an ABI 7900HT
Real-Time PCR System (Applied Biosystems, Foster City,
CA) and analyzed using SDS 2.3 software (Applied
Biosystems, Foster City, CA).
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Creatinine clearance (CrCl) was measured by a 24-hour
urine collection in all participants. At the intake
appointment, participants were provided with a 3-L col-
lection jug and instructed to save all urine between the
end of their intake appointment and the time when a
researcher recovered the urine. Participants were
instructed to keep the urine collections refrigerated at
all times. Research personnel arrived at the participants’
home 24 h after their inception appointments to ensure
accurately timed specimens. At that time, participants
were asked about the time of their first and last voids.
When more than 1 h had passed since their last void,
participants were instructed to void at that time to com-
plete the collection. All participants were asked whether
they were able to collect all urine or whether some frac-
tion had been inadvertently discarded. When the sample
was reported to be incomplete, participants were asked
to repeat the collection, and research personnel returned
24 h later to re-collect the urine. When the 24-h urine
volume was <1 L, participants were asked to repeat the
collection to ensure an adequately collected specimen.
Similarly, when the 3-L collection jug was completely
full, participants were given two new jugs and asked to
repeat the collection to ensure that no urine was inad-
vertently discarded. When participants were unable to
collect all urine for any reason or had urinary inconti-
nence, their samples were deemed inadequate and no
data were recorded for these participants. CrCl was cal-
culated using the following formula: urine creatinine
(mg/dl) * 24-h urine volume (dl)/serum creatinine (mg/
dl) * 1440 (min/d). This procedure was repeated at the
5-year follow-up visit. Baseline kidney function was also
estimated by GFR equations using either creatinine [11]
or cystatin C [12].
Uromodulin Measurement Methods
Uromodulin was measured by the method of Lau et al
with slight modifications. [13] 96-well microtiter plates
were coated with 100 μlo f1 0μg/ml lectin WGA over-
n i g h ta t4 ° C .P l a t e sw e r ew a s h e da n db l o c k e dw i t h2 0 0
μl blocking buffer (3% BSA in PBS) for 2 hours at room
temperature, then washed again and allowed to dry at
37°C for 3 hours. After cooling to room temperature,
plates were sealed and stored at 4°C. Urine samples and
standards (Biomedical Techologies, Stoughton, MA)
were diluted in TEA buffer (0.5% triton X-100, 20 mM
EDTA, pH 7.5) and added to wells in duplicate. After
one hour incubation at 37°C, wells are washed and anti-
uromodulin antibody (Biomedical Techologies,
Stoughton, MA) was added. After one hour incubation
at 37°C, wells were washed and goat anti-rabbit IgG
horseradish perxiodase (Bio-Rad, Hercules, CA) was
added. After 1 hour incubation at 37°C, wells are
washed and color was developed by the addition of
TMB substrate solution and incubation at room tem-
perature for 15 minutes. The reaction is stopped by add-
ing 2N H2SO4, followed by reading immediately at
OD450 and OD620. Urinary uromodulin concentration
was determined by referring to standard curve. [13]
Statistical Analysis
The analysis began with Study 1, the comparison of
UMOD genotype with baseline characteristics among
the 879 participants with available DNA. These compar-
isons were stratified by race- Whites and non-Whites.
Characteristics included demographics (age, sex, race),
body mass index, prevalent hypertension and diabetes,
and the urine albumin to creatinine ratio (ACR). Unad-
justed comparisons were made by the Kruskall-Wallis
test, Chi-square, or Fisher’s exact test. We next com-
pared baseline kidney function across genotype cate-
gories, using measured CrCl and estimated GFR by
cystatin C and creatinine, separately. Because the T/T
genotype group appeared to differ compared with the
G/G and G/T groups, we also compared T/T versus all
others using non-parametric statistics.
Our next step, Study 2, was to compare urine uromo-
dulin concentrations by genotype using unadjusted and
adjusted linear regression with log-transformed urine
uromodulin as the outcome (N = 120). These analyses
were repeated with restriction to Whites only. For Study
3, we compared uromodulin levels between incident
CKD cases and controls (N = 196). The median uromo-
dulin concentration, uromodulin-to-creatinine ratio
(UCR), and total daily uromodulin were compared by
descriptive statistics. We categorized both uromodulin
and UCR into quartiles defined using cutpoints from the
control group; the distribution of cases and controls
across quartiles was evaluated using the Chi-square sta-
tistic. Then, we evaluated uromodulin, UCR levels, and
total uromodulin as continuous variable predictors (log-
transformed per SD) of case-control status using multi-
variate conditional logistic regression, adjusted for
demographic characteristics, body mass index, hyperten-
sion, and diabetes.
Results
Among the 527 self-described White participants with
DNA, 373 (71%) were homozygous for the dominant
allele (G/G), 133 (25%) were heterozygous (G/T) and
only 21 (4%) were homozygous for the minor allele
(T/T). The small T/T group was somewhat younger
than the G/G and G/T genotype groups (Table 1). Base-
line kidney function appeared better in the T/T group
compared with the large G/G and GT groups, as we
previously observed. [1] The T/T genotype had an
approximately 11 ml/min higher CrCl, and 8 ml/min/
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2 higher eGFRcys, and 4 ml/min higher eGFRcr;
none of these differences reached statistical significance.
Baseline kidney function was similar between the G/G
and G/T genotypes. Among 352 non-Whites, 88% were
the dominant G/G genotype, 11% were heterozygous,
and only 1% (N = 3) were homozygous for the minor
allele. Characteristics across these categories are shown
in Table 1.
UMOD genotype was associated with urine uromodu-
lin concentration - the median was more than 50% higher
in the G/G group compared with the T/T genotype, and
heterozygotes (G/T) had intermediate levels (Table 2). In
both unadjusted and adjusted linear regressions, the T/T
genotype had significantly lower uromodulin levels than
the common G/G genotype, but differences between the
G/T and G/G genotypes were not statistically significant.
These findings were essentially unchanged when we
restricted to White participants.
As a result of the matched design, the 102 cases and
94 controls with uromodulin measures, matches were
similar in age, sex, and race (Table 3). Although all
cases and controls had baseline CrCl > 70 ml/min, CrCl
was significantly lower at baseline among future cases
than controls. However, the average change in CrCl was
more than 2-fold among cases compared with controls.
Cases also had a more than 3-fold increase in serum
creatinine and a near doubling in eGFR decline com-
pared with controls. Uromodulin levels were similar
between cases and controls, regardless of whether the
comparison was made of uromodulin concentrations,
UCR, or by 24-hour uromodulin (Table 3). Using condi-
tional logistic regression, each higher SD of baseline
uromodulin or UCR had no significant association with
odds of incident CKD. We also compared the distribu-
tion of quartiles of uromodulin concentrations and UCR
by case-control status; no differences were observed (all
p-values > 0.20). Finally, we compared the UMOD geno-
types among cases and controls. There was no signifi-
cant difference in the distribution (p-value = 0.33), but
the protective T/T genotype appeared less frequent in
cases than controls (2% vs. 5%).
Discussion
The role of uromodulin in the onset and progression of
kidney disease is currently of great interest in clinical
nephrology. Disorders in the UMOD gene lead to the
early onset of severe kidney disease. [3] A more com-
mon variant in the UMOD genotype has been associated
Table 1 Characteristics of Participants in the Heart and Soul Cohort by Genotype
Characteristics G/G
(n = 683)
G/T
(n = 172)
T/T
(n = 24)
P value P Value TT vs. Other
Whites
N 373 133 21 - -
Age 68 ± 11 69 ± 10 64 ± 12 0.24 0.20
Male 86% 86% 86% 0.99 0.58
Body Mass Index 29 ± 5 29 ± 6 30 ± 6 0.48 0.23
Hypertension 66% 65% 81% 0.35 0.11
Diabetes 23% 15% 14% 0.11 0.34
Albumin-creatinine ratio (median, IQR) 10 (7-18) 8 (6-12) 9 (7-20) 0.23 0.86
Baseline Kidney Function
Creatinine Clearance (mean) 92 ± 36 93 ± 34 103 ± 40 0.28 0.12
eGFR (cysC) (mean) 69 ± 22 69 ± 21 79 ± 25 0.20 0.08
eGFR (Scr) (mean) 73 ± 20 74 ± 19 78 ± 22 0.51 0.38
Non-Whites
N 310 39 3 - -
Age 65 ± 11 64 ± 9 57 ± 7 0.27 0.13
Male 77% 82% 33% 0.14 0.13
Body Mass Index 28 ± 6 29 ± 5 38 ± 8 0.02 0.02
Hypertension 78% 77% 100% 0.65 0.47
Diabetes 36% 31% 33% 0.82 0.71
Albumin-creatinine ratio (median, IQR) 11 (7-36) 11 (6-16) 49 (20-78) 0.35 0.15
Baseline Kidney Function
Creatinine Clearance (mean) 90 ± 37 92 ± 40 105 ± 26 0.66 0.39
eGFR (cysC) (mean) 72 ± 25 75 ± 22 72 ± 21 0.83 0.84
eGFR (Scr) (mean) 76 ± 27 82 ± 24 71 ± 10 0.29 0.59
P values are obtained using Kruskal-Wallis rank or the Mann-Whitney test for continuous variables, Fisher’s exact test or Chi-square test for categorical variables.
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[1] Higher urine concentrations of uromodulin were
associated with subsequent development of CKD in the
FHS, a community-based, predominantly White study.
[5] However, in this study from the Heart and Soul
cohort of persons with established CAD, we found no
association between urine concentrations of uromodulin
or total daily uromodulin and incident CKD. Yet,
UMOD genotype was associated with urine uromodulin
levels in a similar direction to the FHS and ARIC
studies.
Several potential reasons could explain why findings in
this study regarding the association of uromodulin and
C K Dd i f f e rf r o mo u rp r i o rw o r ki nF H S .M o s ti m p o r -
tantly, the progression of CKD may be proportionally
related to different mechanisms between persons with
and without CAD. Among the Heart and Soul cohort,
kidney function decline may be caused predominantly
by atherosclerotic mechanisms. Whatever role urine
uromodulin concentrations may have in promoting
kidney decline may be less influential relative to the role
of microvascular disease. A second possibility would be
measurement error, as we developed our own uromodu-
lin assay. However, our replication of the association
between UMOD genotype and urine levels suggests that
our assay functioned accurately. In addition, chance
could have led us to miss an association between urine
uromodulin levels and incident CKD, but our findings
were robustly null and the confidence interval around
the odds ratio for incident CKD was relatively narrow
(0.71-1.26), and clearly excluded the 71% increased odds
observed in FHS. Furthermore, our cohort was a mix
of Whites and non-Whites and other factors may predo-
minate in non-Whites [14]. Finally, cases and controls
differed in their baseline CrCl, while a similar imbalance
of baseline eGFR was present in the FHS analysis.
Despite the null result of our primary hypothesis, this
study has several strengths. To our knowledge, this is
only the second study to evaluate uromodulin concen-
trations as a predictor of incident CKD; although an
exciting potential biomarker, urine uromodulin levels
should be evaluated in multiple diverse settings to deter-
mine their potential value in clinical medicine. The
Heart and Soul cohort had several unique attributes,
including measured kidney function by CrCl on two
occasions, the availability of stored urine and genetic
material, and a 5-year follow-up interval. The primary
limitation was a limited sample size to evaluate homozy-
gotes for the minor allele; however, this group has a
population prevalence of only 3-4%, so much larger stu-
dies are required to characterize them further. A second
limitation is the sample size of our nested case-control
design; yet, the confidence intervals do not suggest that
we would have missed an important finding by chance
alone. A third limitation could be errors in the urine
collections leading to biased estimates of CrCl; however,
cases had much larger changes in creatinine than con-
trols, as well.
Conclusions
In summary, in this cohort of persons with established
coronary artery disease, we replicated the association of
UMOD genotype with urine levels but found no associa-
tion between urine uromodulin concentrations and inci-
dent CKD. The differences from the initial report
suggest that differences in population, urine collection
and measurement may influence the results. Future
s t u d yw i l lb er e q u i r e dt od e t ermine the value of urine
Table 2 Association of UMOD Genotype at rs12917707 and UMOD Levels
Characteristics G/G (n = 48) G/T (n = 48) T/T (n = 24) P value
Overall
UMOD (median IQR) 142 (87-249) 128 (64-207) 83 (33-159) 0.11
Linear Regression (log transformed) (b Coefficient, p-value)
Unadjusted Reference -0.2 -0.7 -
p = 0.36 p = 0.002
Adjusted * Reference -0.2 -0.8 -
p = 0.38 p = 0.001
Restricted to Whites
UMOD (median IQR) 152 (105-268) 129 (67-207) 97 (33-170) 0.23
Linear Regression (log transformed) (b Coefficient, p-value)
Unadjusted Reference -0.4 -0.8 -
p = 0.09 p = 0.001
Adjusted * Reference -0.4 -0.9 -
p = 0.10 p < 0.001
P values are obtained using Kruskal-Wallis rank test for mean comparison and non-parametric median test for median comparison.
*Adjusted for age, sex, race, BMI, diabetes, and hypertension.
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ing risk for the onset and progression of CKD.
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Male 85% 86% 0.86
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Change in CrCl (mean) -42 ± 20 -18 ± 25 <0.001
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Change in creatinine 0.36 0.10 <0.001
Baseline eGFRcr 74 85 <0.001
Final eGFRcr 55 75 <0.001
Change in eGFRcr 19 10 <0.001
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Urine uromodulin-creatinine ratio (mg/g) (median, IQR) 51 (26-75) 47 (23-83) 0.34
24-hour urine uromodulin (mg) (median, IQR) 71 (35-110) 77 (39-121) 0.75
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Urine uromodulin-creatinine ratio (per SD) 1.05 (0.77-1.43) Reference 0.76
24-hour urine uromodulin concentration (per SD) 1.01 (0.74-1.36) Reference 0.97
Genotype Frequencies: 0.33
G/G genotype frequency 79% 72%
G/T genotype frequency 19% 22%
T/T genotype frequency 2% 5%
†cases and controls matched on age, sex, and race.
*UMOD non-detectables set as zero; no difference when excluded non-detectables.
CrCl = creatinine clearance.
IQR = interquartile range; SD = standard deviation.
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